Manuso said at one point that "Premier Pricing has taken effect" when he was taking about Dacogen pricing in the EU for AML. Said the 10,000 potential patients over 65 with AML was greater than the potential market in US. Not sure if I totally understand his quote but it appears that they are getting maximum revenue from Dacogen because it is the only treatment for AML in EU.
After more than a decade of BS, Power Point, hype of CLIMB and PYRIMOD; all I care to hear about is Phase III. I would believe that everyone else feels the same. How long can you go as a Biotech Development company with no marketable results?
This is when we will see some real positive movement.
You state we have no marketable results...dacogen doing $60M, AML approval and $1.37B in milestones ahead of them. If we had a ph3 drug approval right around the corner, this would be $20 stock. We are buying and holding this stock in advance of the near term event.
The only person not happy about a run from 2.31 to 3.40 is you.